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relation to disease severity.  
 
INTRODUCTION 
There is increasing evidence that the frequency of 
atopic diseases including atopic dermatitis has 
increased over the last few decades with prevalence 
rates ranging between 10-20%1. Atopic dermatitis 
(AD) is a chronic relapsing inflammatory skin 
disease seen in patients with a personal or family 
history of atopy. Understanding the mechanisms 
that underlie AD has important clinical implications 
for the development of new management protocols 
for this illness2.                                                                       
IgE-mediated mechanisms play a mutlifactorial 
role in the pathogenesis of AD. Serum IgE levels 
are elevated in 80-85% of AD patients and is 
considered an important hallmark of the disease3. 
Eosinophilia is another important finding in the 
peripheral blood of the allergic type4 and 
eosinophils play an effector role in AD as they 
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migrate from the blood into lesional skin and 
release cytotoxic mediators4. TH2 cytokines as IL-
45,6 and IL-57 are usually elevated in peripheral 
blood of AD patients. Their elevation contributes to 
the elevated peripheral blood IgE level 8,9,10. 
Leukotrienes (LTs) are phospholipids derived 
from arachidonic acid in a pathway involving 
phospholipase 5-lipoxygenase and 5-lipoxygenase-
activating proteins. The cysteinyl LTs (LTC4, 
LTD4 and LTE4) are inflammatory mediators 
which are suggested to play an important role in the 
pathogenesis of AD although their exact cellular 
source in patients with AD is not specified 
(possibly eosinophils, basophils, and mast cells)11. 
LTE4 is a stable urinary metabolite of LTC4 and 
LTD4, and is a useful index for the body production 
of these cysteinyl leukotrienes12. 
With this as background we thought to 
investigate the role of urinary LTE4 in AD and 
anticipate its possible correlation with clinical 
severity and other laboratory parameters as absolute 
eosinophilic count, serum  IgE and IL-4 and IL-5 
levels in PBMC culture supernatant. 
  
METHODS 
This study was conducted on 30 children and 
adolescents diagnosed to have atopic dermatitis 
according to the UK refinement of Hanifin and 
Rajka's diagnostic criteria for AD13. They were 
recruited consecutively from the outpatient clinics 
of the Pediatric and Dermatology Departments of 
Ain Shams University Hospitals. They were 14 
males and 16 females and their ages ranged 
between 3.7 and 11.2 years with mean age of 7.4 ± 
2.6 years. Atopic dermatitis was graded into mild, 
moderate and severe according to the grading 
system of Rajka and Langeland14. Accordingly, 5 
patients were considered to have mild , 16 had 
moderate and 9 had severe AD.  
Inclusion criteria: 
Patients stopped systemic and topical treatments 
before the study for at least one month and 2 weeks 
respectively. Antihistaminics were also stopped one 
week before the study and only topical emolliants 
were used. Patients who concomitantly had any 
chronic systemic illness or  dermatologic diseases 
apart from atopic dermatitis were excluded from the 
study.  
Controls: 
Ten apparently healthy age and sex matched 
children and adolescents were included as controls. 
They were 5 males and 5 females and their ages 
ranged between 3.8 and 11.7 years with mean age 
of 6.9 ± 2.8 years. They were enrolled after 
exclusion of a personal or family history of atopy or 
chronic systemic or dermatologic diseases. 
An informed consent was obtained from parents of 
each subject.  
 
Measurements: 
Patients were subjected to the following: 
1. History taking laying stress on personal and/ or 
family history of atopy, distribution of skin 
lesions and effect of allergens and emotional 
stress on skin lesions. History of  recurrent 
conjunctivitis and skin infections was also sought 
for. 
2. Clinical examination to exclude systemic 
illnesses, stunted growth and nutritional 
disorders. 
3. Skin examination for xerosis, icthyosis, palmar 
hyperlinearity, cutaneous infection, Dennie 
Morgan infraorbital folds, orbital darkening, 
mask of atopic dermatitis, hyperpigmentation, 
scaling, lichenification and white dermographism 
as well as assessment of severity according to the 
grading system of Rajka and Langeland14. 
4. The following laboratory investigations were 
performed for patients and controls: 
I-Complete blood count using Coulter cell counter 
T660 (Coulter corporation, Florida, USA) with 
examination of Leishman stained peripheral 
blood (PB) smears for estimation of the absolute 
eosinophilic count. 
II- Measurement of urinary LTE4 by ELISA 
(Neogen, Lexington, KY, USA). Urine samples 
were collected after 6 hours without voiding, kept 
at -70°C till the time of measurement. After 
extraction, 1ml of urine was acidified to pH 3.5 
with 1 NHCL. Preparation of standards was done 
followed by addition of lμl of conjugate to 50 μl 
total volume of EIA buffer then, 50 μl of 
standards and samples were added to wells in 
duplicate. 50 μl of the diluted enzyme conjugates 
were added to each well and mixed by gentle 
shaking, covered and incubated for 1 h at room 
temperature. 20 ml of wash buffer was diluted in 
180 ml of deionized water. After incubation, 
contents were dumped out then tapped out 
thoroughly on a clean towel and washed three 
times. Addition of 150 μl substrate to each well 
followed by 30 minutes incubation were done. 
Gentle shaking and reading the plate in 
microplate reader was done15.  
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III-Creatinine in the urine was determined using a 
creatinine test kit (Wako Pure Chemical 
Industries, UK). The results displayed are 
corrected values. 
IV- Quantitative determination of serum IgE 
concentrations: 2 ml of venous blood were 
collected in a tube, left to clot and centrifuged at 
1500 rpm to separate the serum. Estimation of 
serum levels of IgE were  done using the ELISA 
technique. (Pathozme IgE, Omega Diagnostic 
Limited, UK)16. 
V- Measurement of levels of IL-4 and IL-5 in 
PBMC culture supernates: Five ml of venous 
blood were drawn aseptically into a disposable 
syringe containing heparin- free preservative to 
give a final concentration of 10 IU/ml of blood. In 
sterile centrifuge tubes, 5 ml blood were carefully 
layered over 3 ml sterile ficoll hypaque mixtured 
and centrifuged for 15 minutes, followed by 
collection of mononuclear cells being washed 
twice in sterile complete RPMI 1640 (Gibco, 
Grand Island, NY, USA). It contained L-
Glutamine, penicillin, streptomycin and N-2 
Hydroxyethyl piperazine and was centrifuged for 
10 minutes. The final cell pellet was gently 
tapped and re-suspended in a known volume of 
complete RPMI 1640 medium to which 200 μl of 
PHA was added as mitogen and incubated for 72 
h at 37°C in 5% C02. The suspension was taken 
in a test tube, centrifuged and kept at 20°C till 
time of assay. Estimation of culture supernatant 
IL-4 and IL-517 was done by sandwich enzyme 
immunoassay technique (R & D Systems, Inc., 
Mckinley Place NE, Minneapolis, USA). 
 
Statistical analysis: 
The data were analyzed statistically using SPSS 
statistical package version 11 using student t-test 
for independent samples as well as ANOVA 
(analysis of variance), post hoc and Pearson's 
correlation coefficient (r) tests. p values < 0.05 
were considered significant. 
 
RESULTS 
The AD patients were found to have 
significantly higher levels of  absolute eosinophilic 
count, urinary LTE4, serum IgE and IL-4 in PBMC 
culture supernatant fluid (p<0.001)  as well as 
PBMC IL-5 (p<0.05) compared to the controls 
(Table 1). 
Table 2 shows that urinary LTE4 levels were 
significantly higher in moderate as well as severe 
cases of AD than controls,  whereas mild cases 
were comparable to controls in urinary LTE4 
levels. Urinary LTE4 mean level was also higher in 
severe (p<0.001) and moderate cases (p<0.05) as 
compared to mild cases. However, no significant 
difference could be elicited between moderate and 
severe cases (Fig.1). The absolute eosinophilic 
count was significantly elevated in moderate 
(p<0.05) and  severe (p<0.01) cases of AD as 
compared to controls. Again, it was significantly 
higher in severe compared to mild and moderate 
cases, while no statistically significant difference 
was found between mild cases and  controls or 
between mild and moderate cases of AD. The 
serum total IgE levels were significantly higher in 
moderate (p<0.05) and severe (p<0.01) cases of  
AD than the control group and were significantly 
increased in severe as compared to moderate and 
mild cases of AD. On the other hand, no 
statistically significant difference  was detected 
between mild and moderate cases or between mild 
cases and controls. A highly significant elevation 
was found in the mean level of PBMC-IL-4 in 
moderate and severe cases of AD as compared to 
controls and in severe AD patients as compared to 
mild and moderate cases. It was also significantly 
increased in moderate  as compared to mild cases of 
AD. On the contrary, its level in mild AD cases was 
comparable to that of controls. The mean level of 
PBMC-IL-5 was significantly higher in severe 
cases of AD as compared to controls and to mild 
and moderate cases of AD. However, other groups 
were comparable in their PBMC IL-5 mean levels. 
Urinary LTE4 could be positively correlated to 
disease severity scores (r=0.69, p<0.001), absolute 
eosinophilic count (r=0.41, p< 0.001),  serum total 
IgE (figure 2) and PBMC IL-4 (figure 3). On the 
other hand, urinary LTE4 did not correlate 
significantly to PBMC IL-5 (r= 0.3, p> 0.05). 
 
 

































F value by ANOVA test = 12.009 ( p<0.01) 
AD: atopic dermatitis; LTE4: leukotriene E4. 
Figure 1: Variation of urinary LTE4 of enrolled 
subjects according to AD severity in comparison 
to controls. 
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Table 1: Laboratory parameters of the studied sample. 
Laboratory parameters AD Patients (n=30) Controls (n=10) t value p value 
Urinary LTE4  
(pg/mg creatinine) 136.13± 62.18 57.10 ± 12.46 6.58 <0.001 
Absolute eosinophilic count 
(109/L) 0.64 ± 0.49 0.18 ± 0.13 4.71 <0.001 
Serum total IgE  
(u/ml) 1019.27± 937.70 63.41 ±29.67 5.04 <0.001 
PBMC-IL-4  
(u/ml) 90.99 ± 68.80 0.53 ±0 .45 7.20 <0.001 
PBMC-IL-5  
(u/ml) 17.74 ± 14.03 0.39 ±0.34 4.45 <0.05 
AD: atopic dermatitis; IgE: immunoglobulin E; IL-4: interleukin-4; IL-5: interleukin-5; PBMC: peripheral 
blood mononuclear cells. 
 
Table 2: Variation of laboratory parameters of enrolled subjects according to AD severity in 























































± 0.46 >0.05 >0.05 <0.01 <0.05 <0.01 <0.01 





























± 11.45 >0.05 >0.05 <0.01 >0.05 <0.01 <0.01 
AD: atopic dermatitis; IgE: immunoglobulin E; IL-4: interleukin-4; IL-5: interleukin-5; PBMC: peripheral blood mononuclear cells. 
 
r = 0.78        p<0.001
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LTE4: leukotriene E4. 
Figure 2: Positive correlation between urinary 
LTE4 and serum total IgE. 
 
r = 0.77     p<0.001
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LTE4: leukotriene E4; PBMC: peripheral blood mononuclear cells. 
Figure 3: Positive correlation between urinary 
LTE4 and PBMC IL-4. 
 
DISCUSSION 
The mean level of urinary LTE4 was significantly 
increased in atopic dermatitis patients compared to 
the control group (p<0.001). The same observation 
was reported by Fauler et al18 and Hishinuma et al2. 
The enhanced urinary excretion of cysteinyl LTs 
can result from either enhanced synthesis or 
reduced hepatic elemination18. Since all our patients 
suffered no hepatic problems, so the increase in 
urinary LTE4 levels actually reflects an enhanced 
synthesis of these metabolites. This supports the 
role of cysteinyl LTs in the pathogenesis of AD 
which is probably mediated through increasing 
vascular permeability and dilating the skin blood 
vessels thus contributing to the inflammatory 
reaction in AD19. 
In contrast to our results, Sansom et al20 found 
no significant difference in urinary LT levels in AD 
patients compared to the control group. This might 
be due to sample to sample variability within an 
individual which thus necessitates evaluation of 
multiple samples or longer urine collection rather 
than a single sample collected during a short 
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period21. This was considered in our study by taking 
urine sample after at least 6 hours without voiding. 
Urinary LTE4 expression was significantly 
higher in moderate and severe cases of AD than 
mild ones. We also noticed a significantly positive 
correlation between LTE4 and disease severity. 
Despite the limited number of our series, the 
available data may suggest a beneficial value of 
LTE4 urinary level estimation as a simple, non 
invasive, objective prognostic test in AD. In the 
study of Miyoshi et al22, urinary LTE4 levels were 
found significantly elevated in AD children  who 
had severe nocturnal itching compared to those who 
had mild nocturnal itching and they suggested that 
increased production of leukotrienes might be 
relevant to nocturnal exacerbation of itching in 
children with atopic dermatitis. On the contrary, 
Yamamoto et al23, reported that there was an 
increase in the urinary LTE4 in asthmatic patients 
than in normal subjects but there was no correlation 
between such increase in urinary LTE4 and the 
disease severity.   
The current study revealed that the absolute 
eosinophilic count and the mean levels of serum 
IgE, PBMC-IL-4 and PBMC IL-5  were  
significantly increased in patients having AD than 
controls .These results are in agreement with many 
other studies as those of Tang et al6 and Mochizuki 
et al24. We also observed that the aforementioned 
parameters were related significantly to grades of 
clinical severity (Table 2) which comes in 
accordance with other studies as those of Tang et 
al6 and Mochizuki et al24. However, Kaminishi et 
al25, stated that elevated levels of IL-4 in peripheral 
T-cells of patients with atopic dermatitis are not 
correlated with disease severity .  
The above data confirm the importance of 
eosinophilia, increased serum IgE, IL-4 and to a 
lesser extent IL-5 in the pathogenesis of AD. 
Moreover, these data support the immunoregulatory 
abnormalities seen in patients with AD that lead to 
increased expression of Th2 cytokines as IL-4 and 
IL-5 which in turn stimulate the IgE synthesis by B 
cells and are chemotactic to eosinophils with a 
concomitant decrease of IFN-γ26. The number of 
eosinophils and the quantity of their products as 
cationic proteins and major basic proteins are found 
in previous studies to be increased in the peripheral 
blood of patients with AD and this increase was 
proved to be correlated with the clinical severity of 
the skin disease. The eosinophils infiltrate the 
affected skin in response to chemotactic substances 
as IL-4 and IL-5 generated by Th-2 cells. Moreover, 
in patients having AD, the eosinophils show 
enhanced response to these cytokines especially IL-
427. The previous studies proved that about 85% of 
patients with AD have increased amount of total 
IgE. Meanwhile, the mean levels of IgE were 
proved to increase in amounts with increasing 
severity and extent of dermatitis and patients with 
high levels were proved to have poorer 
prognosis28,29. The infiltrating lymphocytes in AD 
are capable of releasing a variety of interleukins 
that may promote mast cell proliferation (IL-3), cell 
surface expression of Fc ε receptors and IgE 
synthesis (IL-4) and eosinophil proliferation (IL-5). 
The presence of IL-4 and IL-5 in the AD lesions 
attract inflammatory cells such as eosinophils and 
macrophages to the area and prolong inflammation 
by preventing their apoptosis. IL-4 can also lead to 
steroid resistance by inducing abnormalities in 
glucocorticoid receptor binding affinity30. 
In the present study, a significant positive 
correlation between urinary LTE4 and the mean 
level of serum  IgE was elicited. This result is in 
accordance with that of Hishinuma et al2  
.Moreover, we report for the first time the presence 
of a significant positive correlation between urinary 
LTE4 and both the absolute eosinophilic count and 
the PBMC IL-4. These findings suggest that 
increased levels of urinary LTE4 in AD might be 
due to increased total cellular response to 
stimulation with IgE which is in turn triggered by 
IL-4 and also suggest that eosinophils might be the 
source of increased cysteinyl LTs in AD and such 
increase in eosinophils could be due to stimulation 
by IL-424. On the other hand,  PBMC IL-5 showed 
no significant correlation with urinary LTE4. 
In conclusion, this study demonstrates an 
increase in urinary LTE4 excretion in AD patients 
reflecting increased whole body production of  
cysteinyl LTs. Moreover, urinary LTE4 in AD 
correlated positively with disease severity making it 
an easy, non invasive, objective prognostic test in 
AD patients. Its correlation with eosinophil count, 
IgE and IL-4 suggests an IgE-dependent 
mechanism for its release and that eosinophils 
might be its possible cellular source. We thus 
recommend clinical trials on the effect of 5-
lipoxygenase inhibitors and LT receptor antagonists 
as additional or alternative lines of therapy in AD. 
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